Expanding treatment options for resectable gastric cancer: Is it a countdown for radiotherapy?

Hizal M., Sendur M. A. N. , Bilgin B., Akinci M. B. , Dede D. S. , Yalcin B.

JOURNAL OF BUON, cilt.24, sa.4, ss.1367-1370, 2019 (SCI İndekslerine Giren Dergi) identifier

  • Cilt numarası: 24 Konu: 4
  • Basım Tarihi: 2019
  • Dergi Adı: JOURNAL OF BUON
  • Sayfa Sayıları: ss.1367-1370


Chemoradiotherapy (CRT) and chemotherapy in the perioperative or postoperative settings are the different neoadjuvant/adjuvant treatment approaches for resectable gastric cancer. After the results of the ARTIST trial, CRT lost its importance on a large scale in the adjuvant setting. Also, according to the results of the CRITICS trial, CRT does not seem beneficial in the perioperative treatment setting. The beneficial effect of neoadjuvant/adjuvant radiotherapy as a therapeutic option became more questionable as the evidence grows, but still needs further studies to identify its effects on a subgroup of patients who have R1 or